Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPO closed on 27 Aug 2026. Allotment 28 Aug 2026, listing 1 Sept 2026. Price band ₹938–₹988, lot 15 shares, GMP +₹185 (18.72%). Track allotment on Allotly.
| Status | Closed |
|---|---|
| Category | Mainboard · NSE & BSE |
| Price band | ₹938–₹988 |
| Lot size | 15 shares |
| Minimum investment | ₹14,820 |
| Issue size | ₹1757 Cr |
| GMP | +₹185 (18.72%) |
| Open date | 24 Aug 2026 |
| Close date | 27 Aug 2026 |
| Allotment date | 28 Aug 2026 |
| Listing date | 1 Sept 2026 |
| Registrar | LINK |
About Symbiotec Pharmalab
Symbiotec Pharmalab is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients, contract development and manufacturing solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its active pharmaceutical ingredient portfolio primarily focuses on steroidal products, while its contract development and manufacturing business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house active pharmaceutical ingredient capabilities to support these offerings. Revenue is generated through the sale of active pharmaceutical ingredients, contract development and…
Strengths
- Operates an integrated business across APIs, CDMO services and complex injectables.
- Has one of India’s largest industrial-scale fermentation capacities with 700 KL capacity.
- Backward integration reduces dependence on external sources for key intermediates.
- Develops differentiated double-chamber injectable products using in-house API capabilities.
- Long-term manufacturing agreements and strategic partnerships support future business growth.
Risks
- Almost all revenue comes from API products, making the business dependent on API demand.
- A large share of revenue comes from a few key customers, and losing them could hurt the business.
- The company depends on key suppliers for raw materials, and supply disruptions could affect operations.
- The company faces intense competition in both the API and CDMO businesses.
- Failure to meet repayment obligations or loan covenants could adversely affect the business and finances.